• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

公开的药企向医疗机构支付的相关数据揭示了潜在的公众隐藏成本。

Open data on industry payments to healthcare providers reveal potential hidden costs to the public.

机构信息

Kelley School of Business, Indiana University, Bloomington, IN, 47405, USA.

Department of Statistics, Indiana University, Bloomington, IN, 47408, USA.

出版信息

Nat Commun. 2019 Sep 20;10(1):4314. doi: 10.1038/s41467-019-12317-z.

DOI:10.1038/s41467-019-12317-z
PMID:31541096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6754508/
Abstract

Healthcare industry players make payments to medical providers for non-research expenses. While these payments may pose conflicts of interest, their relationship with overall healthcare costs remains largely unknown. In this study, we linked Open Payments data on providers' industry payments with Medicare data on healthcare costs. We investigated 374,766 providers' industry payments and healthcare costs. We demonstrate that providers receiving higher amounts of industry payments tend to bill higher drug and medical costs. Specifically, we find that a 10% increase in industry payments is associated with 1.3% higher medical and 1.8% higher drug costs. For a typical provider, for example, a 10% or $25 increase in annual industry payments would be associated with approximately $1,100 higher medical costs and $100 higher drug costs. Furthermore, the association between payments and healthcare costs varies markedly across states and correlates with political leaning, being stronger in more conservative states.

摘要

医疗保健行业参与者向医疗服务提供者支付非研究费用。虽然这些支付可能存在利益冲突,但它们与整体医疗保健成本的关系在很大程度上尚不清楚。在这项研究中,我们将提供者的行业支付的公开支付数据与医疗保险的医疗保健成本数据联系起来。我们调查了 374,766 名提供者的行业支付和医疗保健成本。我们表明,接受更多行业支付的提供者往往开出更高的药品和医疗费用。具体来说,我们发现行业支付增加 10%与医疗费用增加 1.3%和药品费用增加 1.8%相关。例如,对于一个典型的提供者来说,行业支付每年增加 10%或 25 美元,与医疗费用增加约 1100 美元和药品费用增加 100 美元相关。此外,支付与医疗保健成本之间的关联在各州之间差异显著,并与政治倾向相关,在更为保守的州更强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/32040b93fa18/41467_2019_12317_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/0008cee10f62/41467_2019_12317_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/bdb1e87b9c02/41467_2019_12317_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/32040b93fa18/41467_2019_12317_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/0008cee10f62/41467_2019_12317_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/bdb1e87b9c02/41467_2019_12317_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bebe/6754508/32040b93fa18/41467_2019_12317_Fig3_HTML.jpg

相似文献

1
Open data on industry payments to healthcare providers reveal potential hidden costs to the public.公开的药企向医疗机构支付的相关数据揭示了潜在的公众隐藏成本。
Nat Commun. 2019 Sep 20;10(1):4314. doi: 10.1038/s41467-019-12317-z.
2
The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.药品制造商向医生支付的费用与阿比特龙和恩杂鲁胺的医疗保险索赔之间不存在关联。
Cancer. 2017 Nov 15;123(22):4356-4362. doi: 10.1002/cncr.30914. Epub 2017 Jul 27.
3
Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.医药行业支付与高成本药物处方之间的关联:一项使用公开支付数据和医疗保险D部分数据的观察性研究。
BMC Health Serv Res. 2018 Apr 2;18(1):236. doi: 10.1186/s12913-018-3043-8.
4
Drug company payments to General Practices in England: Cross-sectional and social network analysis.英格兰全科医生收到的制药公司付款:横断面和社会网络分析。
PLoS One. 2021 Dec 7;16(12):e0261077. doi: 10.1371/journal.pone.0261077. eCollection 2021.
5
Financial conflicts of interest in dentistry: how much money do providers receive from industry?牙科领域的经济利益冲突:从业者从行业中获得多少收入?
Gen Dent. 2020 Jan-Feb;68(1):56-60.
6
High and rising health care costs. Part 3: the role of health care providers.高昂且不断上涨的医疗保健成本。第3部分:医疗保健提供者的作用。
Ann Intern Med. 2005 Jun 21;142(12 Pt 1):996-1002. doi: 10.7326/0003-4819-142-12_part_1-200506210-00009.
7
Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database.2014 年使用医疗保险和医疗补助服务中心公开支付数据库对放射肿瘤学家的行业支付情况进行检查。
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):19-26. doi: 10.1016/j.ijrobp.2015.09.004. Epub 2015 Sep 16.
8
The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.耳鼻喉科医生的行业支付与品牌处方之间的关联。
Otolaryngol Head Neck Surg. 2019 Oct;161(4):605-612. doi: 10.1177/0194599819852321. Epub 2019 Sep 24.
9
Industry payments and physicians prescriptions: Effect of a payment restriction policy.行业支付与医生处方:支付限制政策的效果。
Soc Sci Med. 2021 Jun;278:113942. doi: 10.1016/j.socscimed.2021.113942. Epub 2021 Apr 16.
10
Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.医生从医药企业获得的报酬与更高的医疗保险D部分处方成本相关。
PLoS One. 2016 May 16;11(5):e0155474. doi: 10.1371/journal.pone.0155474. eCollection 2016.

引用本文的文献

1
Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a retrospective analysis.2016年至2019年日本制药行业向获得董事会认证的心脏病专家支付的非研究款项:一项回顾性分析。
BMJ Open. 2024 Jul 31;14(7):e083445. doi: 10.1136/bmjopen-2023-083445.
2
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.比较英国四个国家的制药公司支付款项:一项横断面和社会网络分析。
BMJ Open. 2023 Mar 29;13(3):e061591. doi: 10.1136/bmjopen-2022-061591.
3
Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study.

本文引用的文献

1
Even arbitrary norms influence moral decision-making.即使是任意的规范也会影响道德决策。
Nat Hum Behav. 2019 Jan;3(1):57-62. doi: 10.1038/s41562-018-0489-y. Epub 2018 Dec 17.
2
Medical Marketing in the United States, 1997-2016.美国的医疗营销,1997-2016 年。
JAMA. 2019 Jan 1;321(1):80-96. doi: 10.1001/jama.2018.19320.
3
Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.药企向医生支付报酬与更高的药物使用量和更昂贵的阿片类镇痛药处方有关。
新冠疫情期间行业向医生支付营销费用的变化:准实验性差异研究
BMJ Med. 2022 Sep 6;1(1):e000219. doi: 10.1136/bmjmed-2022-000219. eCollection 2022.
4
Trends in Industry Payments to Cardiologists From 2014 to 2019.2014年至2019年行业向心脏病专家支付费用的趋势。
Circ Cardiovasc Qual Outcomes. 2023 May;16(5):e009820. doi: 10.1161/CIRCOUTCOMES.122.009820. Epub 2023 Mar 17.
5
Open Data: Implications on Privacy in Healthcare Research.开放数据:对医疗保健研究中隐私的影响。
Blockchain Healthc Today. 2020 Sep 18;3. doi: 10.30953/bhty.v3.144. eCollection 2020.
6
Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief.医生与制药行业的互动:制定政策简报的范围综述。
Front Public Health. 2023 Jan 12;10:1072708. doi: 10.3389/fpubh.2022.1072708. eCollection 2022.
7
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.37 个国家/地区的制药公司向医疗保健专业人员和组织披露支付款项的可及性和质量:一项欧洲政策审查。
BMJ Open. 2021 Dec 16;11(12):e053138. doi: 10.1136/bmjopen-2021-053138.
8
Drug company payments to General Practices in England: Cross-sectional and social network analysis.英格兰全科医生收到的制药公司付款:横断面和社会网络分析。
PLoS One. 2021 Dec 7;16(12):e0261077. doi: 10.1371/journal.pone.0261077. eCollection 2021.
9
In Reply to Halperin.回复哈尔珀林。
Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):573-574. doi: 10.1016/j.ijrobp.2021.05.118.
10
Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.抗血小板药物相关行业支付与心脏介入手术和支架使用的关联。
J Gen Intern Med. 2022 May;37(7):1626-1633. doi: 10.1007/s11606-021-06980-6. Epub 2021 Aug 10.
PLoS One. 2018 Dec 19;13(12):e0209383. doi: 10.1371/journal.pone.0209383. eCollection 2018.
4
Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.医药行业支付与高成本药物处方之间的关联:一项使用公开支付数据和医疗保险D部分数据的观察性研究。
BMC Health Serv Res. 2018 Apr 2;18(1):236. doi: 10.1186/s12913-018-3043-8.
5
Health Care Spending in the United States and Other High-Income Countries.美国和其他高收入国家的医疗保健支出。
JAMA. 2018 Mar 13;319(10):1024-1039. doi: 10.1001/jama.2018.1150.
6
Challenges in Understanding Differences in Health Care Spending Between the United States and Other High-Income Countries.理解美国与其他高收入国家医疗保健支出差异所面临的挑战。
JAMA. 2018 Mar 13;319(10):986-987. doi: 10.1001/jama.2018.1152.
7
The Real Cost of the US Health Care System.美国医疗保健系统的实际成本。
JAMA. 2018 Mar 13;319(10):983-985. doi: 10.1001/jama.2018.1151.
8
Factors Contributing to Higher Health Care Spending in the United States Compared With Other High-Income Countries.与其他高收入国家相比,导致美国医疗保健支出较高的因素。
JAMA. 2018 Mar 13;319(10):988-990. doi: 10.1001/jama.2018.1149.
9
Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.医生与制药行业(总体而言)以及销售代表(具体而言)之间的互动及其与医生态度和处方习惯的关联:一项系统综述。
BMJ Open. 2017 Sep 27;7(9):e016408. doi: 10.1136/bmjopen-2017-016408.
10
Strategies for Addressing a Broader Definition of Conflicts of Interest.应对利益冲突更广泛定义的策略。
JAMA. 2017 May 2;317(17):1727-1728. doi: 10.1001/jama.2017.3857.